VistaGen Therapeutics(VTGN) - 2024 Q4 - Annual Results

Fasedienol for the Acute Treatment of Social Anxiety Disorder (SAD) Exhibit 99.1 Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3 Phase 3 trial recently initiated; PALISADE-4 Phase 3 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)—February 13, 2024-- Vistagen (Nasdaq: VTGN), a neuroscience- focused b ...